Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Parabilis Medicines Inc (PBLS)

79 + Investors. Track Smart Money conviction in PBLS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%

79+

Inst. Holders

Hedge Fund Ownership: PBLS

How many hedge funds hold PBLS — quarterly history vs. share price
Quarterly hedge fund ownership of PBLS vs. share price

Market Analysis: PBLS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: PBLS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Loading signal freshness…
Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

6 top-rated funds 6 high-conviction
Consensus
3.7
/ 10
breadth
×
Elite
3.7
/ 10
conviction
Hedge Fund Positioning: PBLS
2026 Q3 Stats Unlock in 9 days 79 + Investors

Track Smart Money conviction in PBLS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 79 0 100%
13F Shares 97M 0 100%
Total Value $2.63B $0 100%
New Positions 79 0 +79
Increased Positions 0 0 -
Closed Positions 0 0 -
Reduced Positions 0 0 -
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: PBLS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

79 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PBLS. Verified SEC 13F-HR filings.

Top 25 PBLS holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Regeneron Pharmaceuticals, INC. 64.35% 4,166,666 $114.0M
2 venBio Partners LLC 27.75% 5,266,697 $144.1M
3 General Catalyst Group Management, LLC 23.24% 1,600,937 $43.8M
4 ARCH Venture Management, LLC 15.95% 6,412,780 $175.5M
5 Ra Capital Management, L.P. 6.88% 28,933,371 $791.9M
6 Cormorant Asset Management, LP 6.47% 4,615,612 $126.3M
7 Nextech Invest Ltd. 6.06% 4,663,176 $127.6M
8 Foresite Capital Management VI LLC 4.26% 999,044 $27.3M
9 Catalio Capital Management, LP 4.24% 824,043 $22.6M
10 Siren, L.L.C. 1.66% 2,992,259 $81.9M
11 General Atlantic, L.P. 1.45% 1,538,461 $42.1M
12 Soleus Capital Management, L.P. 1.38% 1,465,070 $40.1M
13 Samsara BioCapital, LLC 1.25% 556,044 $15.2M
14 Frazier Life Sciences Management, L.P. 1.14% 1,920,805 $52.6M
15 Casdin Capital, LLC 0.88% 645,690 $17.7M
16 Rock Springs Capital Management LP 0.77% 578,028 $15.8M
17 Logos Global Management LP 0.62% 525,000 $14.4M
18 Deerfield Management Company, L.P. 0.54% 1,880,704 $51.5M
19 Venrock Adviser, LLC 0.52% 625,000 $17.1M
20 Kynam Capital Management, LP 0.38% 250,000 $6.8M
21 Bellevue Group AG 0.29% 500,000 $13.7M
22 ICONIQ Capital, LLC 0.28% 350,000 $9.6M
23 Scientech Research LLC 0.21% 9,564 $262K
24 Alphabet Inc. 0.14% 4,919,498 $134.6M
25 Baker BROS. Advisors LP 0.07% 500,000 $13.7M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Parabilis Medicines Inc (PBLS)

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →